---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-007985"
form_type: "8-K"
ticker: "IRMD"
cik: "0001325618"
company_name: "IRADIMED CORP"
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T21:02:04.552287+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IRADIMED reports record Q1 revenue $15.5M; raises FY 2023 guidance

## Summary
- Q1 revenue $15.5M (+25.7% YoY); GAAP diluted EPS $0.27, non-GAAP $0.30.
- Operating income $4.0M, up 30% YoY; gross margin 75.7% vs 76.2%.
- Paid special dividend of $1.05 per share during Q1.
- Q2 2023 guidance: revenue $15.6-15.8M, non-GAAP EPS $0.30-0.32.
- FY 2023 guidance raised: revenue $62-63.5M, non-GAAP EPS $1.26-1.35.

## SEC filing metadata
- accession: 0001558370-23-007985
- form_type: 8-K
- ticker: IRMD
- cik: 0001325618
- company_name: IRADIMED CORP
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1325618/000155837023007985/0001558370-23-007985-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1325618/000155837023007985/irmd-20230504x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-007985
- JSON: https://secwatch.observer/filing/0001558370-23-007985.json
- Plain text: https://secwatch.observer/filing/0001558370-23-007985.txt

## Key facts
- Earnings Releases
  IRADIMED CORP reported the second quarter of 2023 results: revenue $15.6 million to $15.8 million, EPS $0.27 to $0.29. Guidance initiated.
  - Period: the second quarter of 2023
  - Revenue: $15.6 million to $15.8 million
  - EPS: $0.27 to $0.29
  - Guidance: initiated
  - Result: guidance update
  source text: For the second quarter of 2023, the Company expects to report revenue of $15.6 million to $15.8 million, GAAP diluted earnings per share of $0.27 to $0.29, and non-GAAP diluted earnings per share of $0.30 to $0.32.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1325618/000155837023007985/0001558370-23-007985-index.htm
- Earnings Releases
  IRADIMED CORP reported the first quarter ended March 31, 2023 results: revenue $15.5 million, net income $3.4 million, EPS $0.27 per diluted share.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $15.5 million
  - Net income: $3.4 million
  - EPS: $0.27 per diluted share
  - Result: reported results
  source text: For the first quarter ended March 31, 2023, the Company reported over 25% year-over-year revenue growth to $15.5 million compared to $12.3 million for the first quarter of 2022. Net income was $3.4 million, or $0.27 per diluted share, compared to $2.5 million, or $0.20 per diluted share for the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1325618/000155837023007985/0001558370-23-007985-index.htm
- Earnings Releases
  IRADIMED CORP reported full-year 2023 results: revenue $62 million to $63.5 million, EPS $1.13 to $1.21. Guidance raised.
  - Period: full-year 2023
  - Revenue: $62 million to $63.5 million
  - EPS: $1.13 to $1.21
  - Guidance: raised
  - Result: guidance update
  source text: The Company increased its full-year 2023 financial guidance and now expects to report revenue of $62 million to $63.5 million, GAAP diluted earnings per share of $1.13 to $1.21, and non-GAAP diluted earnings per share of $1.26 to $1.35.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1325618/000155837023007985/0001558370-23-007985-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.